CF PharmTech Sets 31 August 2026 Board Meeting to Review H1 2026 Results and Potential Interim Dividend
Bulletin Express
Aug 19
CF PharmTech, Inc. has announced that its board of directors will convene on 31 August 2026 to deliberate several key agenda items, chief among them the approval and publication of the unaudited interim results for the six months ended 30 June 2026.
The meeting will also consider the declaration of an interim dividend, subject to board approval, alongside other routine corporate matters.
The board is chaired by Dr. Liang Bill Wenqing, who also serves as Executive Director and Chief Executive Officer. The current board comprises five executive directors, two non-executive directors and four independent non-executive directors.
The announcement was released in Hong Kong on 19 August 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.